SCHEMBL2902239

SCHEMBL2902239

CCOC(=O)c1c[nH]c(C(C)C)cc1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
GABRA1 P14867 3/20 0.46
GABRB2 P47870 3/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
LMNA P02545 1/20 0.45
GABRB1 P18505 2/20 0.45
GABRA3 P34903 2/20 0.45
CLEC4M Q9H2X3 1/20 0.45
KDM4E B2RXH2 2/20 0.44
NR1H2 P55055 1/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15333212 0.82 KMT2A (0.53) CYP1A2CYP3A4CYP2C19KMT2AMEN1
SCHEMBL21776563 0.80 KMT2A (0.50) CYP1A2CYP3A4CYP2C19KMT2AMEN1
SCHEMBL17648844 0.76 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19KMT2AMEN1
SCHEMBL1683438 0.72 NR1H2 (0.47) CYP1A2CYP3A4CYP2C19KMT2AMEN1
SCHEMBL1924402 0.72 ALDH1A1 (0.47) CYP1A2CYP2C19KMT2AMEN1ALDH1A1
SCHEMBL24038484 0.71 HPGDS (0.47) CYP1A2CYP3A4CYP2C19KMT2AMEN1
SCHEMBL23732251 0.71 ALDH1A1 (0.46) KMT2AMEN1ALDH1A1MAPTL3MBTL1
SCHEMBL3228479 0.70 CA12 (0.54) CYP1A2CYP3A4CYP2C19KMT2AMEN1
SCHEMBL1127430 0.69 KMT2A (0.49) KMT2AMEN1ALDH1A1MAPTL3MBTL1
SCHEMBL15468562 0.69 BAZ2B (0.54) CYP1A2CYP3A4CYP2C19KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT CYP1A2 388/4885CYP3A4 533/4885CYP2C19 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.